Literature DB >> 21873821

[Primary antibiotic resistance of Helicobacter pylori strains and eradication rate according to gastroduodenal disease in Korea].

Jae Yeon Kim1, Nayoung Kim, Hyun Kyung Park, Hyun Jin Jo, Cheol Min Shin, Sang Hyub Lee, Young Soo Park, Jin Hyeok Hwang, Jin Wook Kim, Sook Hyang Jeong, Dong Ho Lee, Ryoung Hee Nam, Jung Mogg Kim, Ji Hyun Lee, Hyun Chae Jung, In Sung Song.   

Abstract

BACKGROUND/AIMS: This study was performed to evaluate whether the prevalence rates of primary antibiotic resistance in Helicobacter pylori (H. pylori) isolates and the eradication rate of H. pylori could be different between cancer and non-cancer patients.
METHODS: H. pylori were isolated from gastric mucosal biopsy specimens obtained from 269 Koreans, who did not have any eradication therapy history and were diagnosed as one of the following diseases; chronic gastritis, benign gastric ulcer, duodenal ulcer or gastric cancer. The susceptibilities of the H. pylori isolates to amoxicillin, clarithromycin, metronidazole, tetracycline, azithromycin, ciprofloxacin, levofloxacin and moxifloxacin were examined with the agar dilution method. In addition, eradication rate of H. pylori was evaluated.
RESULTS: There was no significant difference in the primary antibiotic resistance to above eight antibiotics among chronic gastritis, peptic ulcer disease and gastric cancer. Furthermore there was no difference of antibiotic resistance between cancer and non-cancer patients, and there was no difference of eradication rate of H. pylori according to disease.
CONCLUSIONS: Primary antibiotic resistance and H. pylori eradication rate were not different between cancer and non-cancer patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21873821     DOI: 10.4166/kjg.2011.58.2.74

Source DB:  PubMed          Journal:  Korean J Gastroenterol        ISSN: 1598-9992


  9 in total

1.  Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.

Authors:  Jae Jin Hwang; Dong Ho Lee; Ae-Ra Lee; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Nayoung Kim
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

2.  Rifaximin Plus Levofloxacin-Based Rescue Regimen for the Eradication of Helicobacter pylori.

Authors:  Sang-Pil Yun; Han Gyung Seon; Chang Soo Ok; Kwang Ho Yoo; Min Kyung Kang; Won Hee Kim; Chang Il Kwon; Kwang Hyun Ko; Seong Gyu Hwang; Pil Won Park; Sung Pyo Hong
Journal:  Gut Liver       Date:  2012-10-18       Impact factor: 4.519

Review 3.  Non-microbial approach for Helicobacter pylori as faster track to prevent gastric cancer than simple eradication.

Authors:  Sang-Ho Park; Napapan Kangwan; Jong-Min Park; Eun-Hee Kim; Ki Baik Hahm
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

4.  Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: is it time to change?

Authors:  Eun Jeong Gong; Sung-Cheol Yun; Hwoon-Yong Jung; Hyun Lim; Kwi-Sook Choi; Ji Yong Ahn; Jeong Hoon Lee; Do Hoon Kim; Kee Don Choi; Ho June Song; Gin Hyug Lee; Jin-Ho Kim
Journal:  J Korean Med Sci       Date:  2014-04-25       Impact factor: 2.153

5.  The efficacy of moxifloxacin-containing triple therapy after standard triple, sequential, or concomitant therapy failure for Helicobacter pylori eradication in Korea.

Authors:  Kwang Hyun Chung; Dong Ho Lee; Eunhyo Jin; Yuri Cho; Ji Yeon Seo; Nayoung Kim; Sook Hyang Jeong; Jin Wook Kim; Jin-Hyeok Hwang; Cheol Min Shin
Journal:  Gut Liver       Date:  2014-11-15       Impact factor: 4.519

Review 6.  Current Status of the Third-Line Helicobacter pylori Eradication.

Authors:  Jae Ho Choi; Young Joo Yang; Chang Seok Bang; Jae Jun Lee; Gwang Ho Baik
Journal:  Gastroenterol Res Pract       Date:  2018-05-02       Impact factor: 2.260

7.  Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection.

Authors:  Seong Tae Lee; Dong Ho Lee; Ji Hyun Lim; Nayoung Kim; Young Soo Park; Cheol Min Shin; Hyun Jin Jo; In Sung Song
Journal:  Gut Liver       Date:  2015-07       Impact factor: 4.519

8.  Levofloxacin, Metronidazole, and Lansoprazole Triple Therapy Compared to Quadruple Therapy as a Second-Line Treatment of Helicobacter pylori Infection in Korea.

Authors:  Ji Yoon Moon; Gwang Ha Kim; Hyun Seok You; Bong Eun Lee; Dong Yeop Ryu; Jae Hoon Cheong; Jung Im Jung; Jae Hoon Jeong; Chul Soo Song; Geun Am Song
Journal:  Gut Liver       Date:  2013-06-11       Impact factor: 4.519

9.  Clarithromycin-based standard triple therapy can still be effective for Helicobacter pylori eradication in some parts of the Korea.

Authors:  Kyu-Hyun Yoon; Sung Woon Park; Sang Wook Lee; Beom Jin Kim; Jae Gyu Kim
Journal:  J Korean Med Sci       Date:  2014-09-02       Impact factor: 2.153

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.